Mylan recalls batches of Nizatidine capsules after nitrosamine detected in API
The US arm of generic and specialty pharma company Mylan Pharmaceuticals has recalled three lots of its heartburn drug Nizatidine in capsule form amid fears of possible nitrosamine contamination.
The voluntary nationwide recall comes after trace amounts of the nitrosamine impurity N-Nitrosodimethylamine (NDMA) were detected in the active pharmaceutical ingredient (API) supplied by India-based Solara Active Pharma Sciences Ltd.
Mylan said it had recalled three lots of Nizatidine capsules, including the 150mg and 300mg strengths, which were distributed to wholesalers, mail order pharmacies, wholesale and retail pharmacies and a distributor between June 2017 and August 2018.
The company has so far not received any reports of adverse events related to these batches, it added.
The action marks the latest in a string of recalls prompted by the potential risk of nitrosamine impurities in medications that have rocked the API manufacturing sector over the last two years.
The US Food and Drug Administration first said it had detected NDMA in Angiotensin II receptor blockers used to treat blood pressure and heart conditions and heartburn drug, ranitidine, sold under the brand name Zantac among others, back in July 2018.
The drug regulator has asked manufacturers of nizatidine and ranitidine to test their products for NDMA and send samples in. It is also conducting ongoing investigations into the presence of nitrosamine in other drug products.
Meanwhile, the European Medicines Agency has asked manufacturers to complete a risk assessment of products potentially affected by 26 March this year.
NDMA, a chemical form of nitrosamine and generally found in water and foods, including processed meats dairy products and vegetables, is classified as a probable human carcinogen that could cause cancer.
Nizatidine is a histamine H2 receptor antagonist used to treat active duodenal ulcers and benign gastric ulcers as well as gastroesophageal reflux disease. It was first approved for medical use in 1987.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance